CN101306015B - Composition for increasing embryo quality and preventing and curing defect baby from generating - Google Patents

Composition for increasing embryo quality and preventing and curing defect baby from generating Download PDF

Info

Publication number
CN101306015B
CN101306015B CN2007101085064A CN200710108506A CN101306015B CN 101306015 B CN101306015 B CN 101306015B CN 2007101085064 A CN2007101085064 A CN 2007101085064A CN 200710108506 A CN200710108506 A CN 200710108506A CN 101306015 B CN101306015 B CN 101306015B
Authority
CN
China
Prior art keywords
vitamin
taurine
folic acid
acetate
baby
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007101085064A
Other languages
Chinese (zh)
Other versions
CN101306015A (en
Inventor
黄胜先
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2007101085064A priority Critical patent/CN101306015B/en
Priority to PCT/CN2008/070973 priority patent/WO2008141570A1/en
Publication of CN101306015A publication Critical patent/CN101306015A/en
Application granted granted Critical
Publication of CN101306015B publication Critical patent/CN101306015B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a combination used for increasing the fetal quality and avoiding the occurrence of defect infant. The combination comprises the following components: green copperas, vitamin C, calcium gluconate, zinc gluconate, taurine, vitamin E acetate, potash iodate, and folic acid. The proportion of the green copperas, the vitamin C, the calcium gluconate, the zinc gluconate, the taurine, the vitamin E acetate, the potash iodate, and the folic acid ranges from 125:125:100:100:60:60:10:1 to 80:80:60:60:40:40:10:1. A method, which is used for preparing the combination for increasing the fetal quality and avoiding the occurrence of defect infant, comprises the steps as follows: (1) qualified materials which are selected from the components of the combination according to the proportion are mixed evenly; (2) a figuration auxiliary material is added in, and the mixture is evenly mixed again; and (3) oral preparation is obtained after the mixture is dried. The combination has remarkable curative effects of increasing the fetal quality and avoiding the occurrence of defect infant and has easy administration; synergistic action is realized by all the components, thereby reducing the toxicity and side effects, and increasing the curative effect.

Description

A kind of compositions that is used to improve embryo quality, the generation of control defect baby
1, technical field:
The present invention relates to a kind of compositions that is used to improve embryo quality, the generation of control fetus defective, relate in particular to a kind of compositions of forming by ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid that is used to improve embryo quality, the generation of control fetus defective.
2, background technology:
Birth defect is also referred to as congenital anomaly, congenital malformation, is meant baby's unusual on the profile that in utero just exists or body inner structure or function, and performance significantly is called congenital diseases.Miscarriage is to eliminate one of natural means of birth defect fetus.
China is populous nation, also is one of birth defect country occurred frequently, and present national people with disability accounts for 4.9% of total population, relates to family and accounts for 18%; The annual neonate birth defect rate in the whole nation is (there is notable difference in various places) about 3-13%, takes place during 0-14 year or the developmental disability rate made a definite diagnosis is 3-6%.1,500,000 defect babies of having an appointment national every year produce, and bring great misery for unfortunate family, bring heavy burden to national, society, family.Neonate health is not only the thing of one family, more is related to a nation's quality that country is following.This is not only a serious public health problem, also is the restriction economic development, influences the social problem of social stability.
As long as everyone can both pay attention to follow-on quality with healthy for we, just can farthest reduce the incidence rate of birth defect, improve whole people's quality.
Form the causality classification analysis of defect baby:
The national maternity and child hygiene monitoring results in 2004 that Ministry of Public Health is announced show, hospital's birth defect youngster incidence rate is in rising trend, and sick class is a lot, and modal 5 kinds of birth defects are followed successively by: congenital heart disease, chapped lip (being commonly called as cleftlip), refer to (toe), neural tube defect, hydrocephalus more.The reason that causes birth defect can be divided into two classes, and a class is an inherited genetic factors, i.e. father and mother's genetic influence itself.Another kind of is environmental factors, mainly comprises nutriture to the deleterious biology of fetal development, chemistry, physics, medicine factor and parent etc.Environmental factors can be controlled and change, below with the further classification declaration of environmental factors:
One, germ cell is unsound:
1, pregnant at the beginning of advanced age.Along with the increase at age, women's ovum wears out and downgrade gradually, and distored probability takes place fetus increases, and fetal anomaly rate and other heredopathia sickness rate also significantly rise;
2, cosmetics, abluent, environmental pollution, virus, chlamydia, mycoplasma, toxoplasma, parasitic infection, radiation, smoking, drink, factor such as medicine all has the effect that reduces the germ cell quality, causes fetal anomaly;
3, few or influenced and absorb fewly with closely related some trace element of reproductive function storage in environment, make the germ cell downgrade;
4, nutrition is unbalanced, finally influences the reproduction function and causes the germ cell downgrade.
Two, embryo's growing environment is undesirable:
1, contraceptive residual interference hormonal system and with the normal absorption of the closely-related material of reproductive function, influence normal fetal development;
2, cosmetics, abluent, medicine, environmental pollution, virus, chlamydia, mycoplasma, toxoplasma, parasitic infection, radiation, smoking, factor such as drink all can cause fetal anomaly;
3, few or influenced and absorb fewly with closely related some trace element of reproductive function storage in environment, make fetal development undesired;
4, gravidic women easily suffers from hyperthyroidism, and the hyperthyroidism meeting causes the fetal nerve phylogeny undesired, at this moment suitable termination of pregnancy;
5, fetus is miscarried or premature labor when serious, even causes kernicterus of newborn and even death in mother's intrauterine generation haemolysis and anemia;
6, pregnant at the beginning of advanced age.This period, puerpera's uterine contraction ability weakened, and the soft birth canal fibrous tissue increases, and the chance of difficult labour increases.In order to improve embryo quality, the generation of control fetus defective, the following several Therapeutic Method of main at present employing:
1, trace element such as supplementing iodine;
2, take Chinese medicine and Chinese medicine health care product;
3, take tocolytic agent.
Said method all has its weak point, wherein, the 1st method, one pack system dosage is big, toxic and side effects obvious and DeGrain; The 2nd method taken inconvenience, the logical relation imprecision of curative effect, and expense is higher; Taking tocolytic agent can only keep fetus but can not improve embryo quality, control fetus defective.
3, summary of the invention:
The object of the present invention is to provide a kind of compositions that embryo quality, control fetus defective produce that is used to improve, said composition is evident in efficacy, taking convenience and having no side effect.
For achieving the above object, compositions of the present invention is to be made of following composition: ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid.
The ratio of ferrous sulfate of the present invention, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid is from 125: 125: 100: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: 10: 1; concrete ratio can be from 125: 125: 100: 100: 60: 60: 10: 1 to 100: 100: 80: 80: 50: 50: also can be from 80: 80: 60: 60: 40: 40: 10: 1 to 100: 100: 80: 80: 50: 50: 10: 1 at 10: 1.
Prepare the above-mentioned method for compositions that embryo quality, control fetus defective produce that is used to improve, be to be made of following steps: (1) is from 125: 125: 100 in the ratio of ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: choose the acceptable material mix homogeneously at 10: 1; (2) add figuration adjuvant mix homogeneously again; (3) make oral formulations after the drying.
Described oral formulations is tablet, granule, capsule.
The present invention compares with present main 3 kinds of Therapeutic Method that adopt, and its beneficial effect is: each component of this medicine is that the pharmacology that filters out through long-term exploration of inventor is complementary collaborative, and effect obviously and the combination that has no side effect, and is evident in efficacy.In actual use, can improve the germ cell quality, optimize the fetal growth environment, stablize fetal genetic information, improve embryo quality, control produces because of the fetus defective that the germ cell cause for quality causes.And medical expense is cheap must not be in hospital again, does not influence routine work and life, can be extensive use of.
The intestines and stomach reaction can appear feel sick waiting in the user of medicine of the present invention only about 0.5%, compares with being used to prevent and treat 3 class methods that the fetus defective produces at present, and the advantage of low untoward reaction aspect is outstanding.
Invention can provide curative effect for following crowd:
1, thinks the children's that quality of prenatal and postnatal care is higher ready-to-be mother, account for women's at reproduction age 100%;
2, taken place miscarriage, produced the imperfect unfortunate women that breed such as defect baby, account for women's at reproduction age 10%;
3, the ready-to-be mother of untoward reaction appears in fetus in the preparation process, accounts for women's at reproduction age 5%.
The specific embodiment:
Therefore the following stated does not limit protection scope of the present invention only for embodying the preferred embodiment of the principle of the invention.
Medicine of the present invention is to be made of following components by weight proportion: the ratio of ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid is from 125: 125: 100: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: 10: 1.
Wherein the effect of each component is:
The effect of ferrous sulfate is: 1, ferrous sulfate is the important composition composition of hemoglobin, and hemoglobin is the ferrous and proteic complex molecule of sulfur acid, and it can carry the histiocyte that oxygen is given fetus and anemia of pregnant woman self.2, the anemia of pregnant woman lacks ferrous sulfate, easily causes anemia, and hemoglobin descends and to cause histanoxia, can cause the anemia of pregnant woman occur nervously breathing hard, dizzy, weak, severe patient can cause myocardial hypertrophy, heart failure, edema etc.; 3, fetus lacks ferrous sulfate, can cause intrauterine fetal anoxia, and growth retardation give birth to back intelligence development obstacle, even the baby within 6 months is easily suffered from nutritional iron deficiency anemia etc.
Ascorbic effect is: 1, vitamin C promotes lymphoblastic generation, strengthens the human body anti-stress ability and the immunity of environment to external world, improves body to the identification of external and malignant cell with kill.2, vitamin C improves the utilization of ferrum, calcium and folic acid.3, a kind of water miscible strong antioxidant of vitamin C.Can protect other antioxidant,, prevent the injury of radical pair human body as vitamin A, vitamin E, unsaturated fatty acid.4, vitamin C can prevent the oxidized of folic acid, the performance of favourable what folic acid normal function.
The effect of calcium gluconate is: 1, calcium gluconate is the important source material of building skeleton and tooth, and the calcium gluconate in the blood is to keeping the activity of normal neurotransmission, muscle contraction, blood coagulation, enzyme, and the biomembrane function plays an important role.2, fetus can not get enough calcium gluconate, is easy to take place the congenital laryngomalacia of neonate, when neonate is air-breathing, geneogenous cartilage curls and contacts with larynx, the porch of very easy obstruction larynx, and produce the sound of snoring, this is very disadvantageous to neonate health.What is more important, fetus ingestion of glucose acid hypocalcia suffers from very easily also after the birth that craniotabes, cephalus quadratus, preceding fontanel closure are unusual, congenital ricketses such as beading of ribs, pigeon chest or funnel brain.3, the anemia of pregnant woman lacks calcium gluconate and can not get replenishing, serious caused lumbago, skelalgia, bone pain, tetany and loss of tooth generation Leg Cramps or tetany, even cause osteomalacia, pelvis distortion, cause difficult labour; Phenomenons such as the loose or loss of tooth of osteomalacia and tooth appear puerperal.
The effect of zinc gluconate is: 1, zinc gluconate can influence growth, growth and the maturation of fetal brain cell.During the gluconic acid zinc deficiency, can make the active influenced of interior 80 plurality of enzymes of body, cause NDA, RNA and protein synthesis obstacle, can cause the fetal brain cell prosoplasia, the brain cell sum reduces; Birth weight and mental retardation, even developmental disordeies such as anencephaly, spina bifida, achondroplastic dwarf, cryptorchidism can appear.2, zinc gluconate disturbs the absorption of noxious substances such as copper-lead to alleviate murder by poisoning to fetus.3, zinc gluconate mainly is the activity that can strengthen atp enzyme in the muscle cell of uterus to the influence of childbirth, promotes uterus muscle to shrink, and the chance of its spontaneous labor strengthens, and alleviates labor pains, reduces postpartum hemorrhage.Otherwise inertia of uterus increases the probability of having difficult labour.
The effect of taurine is: 1, taurine can promote synthesizing of brain cell interior DNA, RNA; promote the growth of abr cell; influence abr cell to the neuronic differentiation of difference; the oriented growth of fiber excites nerve; the adjusting neurotransmitter is synthetic; promote the propagation and the differentiation of cell, promote cerebral tissue and intelligence development.Lacking taurine will cause the 26S Proteasome Structure and Function of fetal tissue's organ unusual.2, taurine can promote the neuronic growth of hippocampus, and prolongs its metabolism time; 3, taurine can carry out " nothing poisons " to the noxious substance monochloramine in the leukocyte, thereby realizes self-protection, and brain is had the certain protection effect
The effect of Vitamin E acetate is: 1, Vitamin E acetate has another name called tocopherol or Vitamin E; can keep the normal function of genitals; metabolism to body has desirable influence; ovary weight is increased; promote its function; corpus luteum is increased, and can suppress progesterone oxidation in vivo, thereby increase the effect of progesterone.2, Vitamin E acetate antioxidation can be stablized embryo's film, improves embryo quality and survival rate, keeps the normal physiological function of histoorgans such as propagating system, nervous system, immune system, the control miscarriage.
The effect of potassium iodate is: 1, potassium iodate is that particularly thyroxin is synthetic and nervous system development institute is requisite for each system of human body.Thyroid plays an important role to the growth of embryo and brain and neurocyte, and potassium iodate also can directly influence the growth of the nervous tissue of fetus, and particularly differentiation and the growth to the part of being responsible for language, audition and intelligence in the fetal brain cortex has a direct impact.Mother trimester of pregnancy lacks potassium iodate, will influence the fetal brain cortical development, and brain weight is alleviated, and the birth back is just very easy to become defective youngsters such as in various degree mental retardation, deaf and dumb, dull-witted, microcephaly, low set ears, paralysis, hyperkinetic syndrome may occur after big slightly.2, because of being that calcium and potassium iodate have antagonism.Because need the potassium iodate amount to increase when conceived, most of anemia of pregnant woman can take calcium preparation, and calcium influences the absorption of iodine, so the quantity delivered of iodine is also wanted corresponding increase.
The effect of folic acid is: (1) folic acid is the synthetic essential factor of protein and nucleic acid, the metabolism of long-chain fatty acid such as DNA in participation hemoglobin, erythrocyte, the quick hypertrophy of leukocyte, amino acid metabolism, the brain.If the anemia of pregnant woman lacks folic acid, just can cause embryonic cell division obstacle, cause unusual, the embryonic cell developmental disorder of embryonic cell division, under-weight appears, harelip, placental abruption, heart defect, particularly because the neurocele developmental disorder causes fetus " anencephaly " or " spina bifida " to occur.(2) folic acid promotes fetal nerve system, corticocerebral growth, improves IQ, allows very intelligent, the requisite vitamin of high iq of baby of giving birth to.(3) folate level is crossed to hang down and also can be brought danger to the anemia of pregnant woman.This be because nucleus maturation delays under the situation of folic acid lacking, the ratio of cell nuclear RNA (ribonucleic acid) and DNA is lacked of proper care thereupon, causes erythrocyte bulky, but nucleus is very immature, just so-called " huge juvenile cell ", therefore Anemia appears in the anemia of pregnant woman.Also can cause anemic cardiopathy, gestation hypertension disease, placental abruption, premature labor and puerperal infection etc. when serious.
Medication preparation of the present invention should be carried out on the oral formulations production line of GMP compatible, and its step is as follows: (1) is from 125: 125: 100 in the ratio of ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: choose the acceptable material mix homogeneously at 10: 1; (2) add figuration adjuvant mix homogeneously again; (3) make oral formulations after the drying.Oral formulations is for making tablet, granule, capsule according to equipment and market demand.
The instructions of taking of medicine of the present invention is as follows: the preceding warm water delivery service of sleeping every day, and each potion, be 3 months each course of treatment.

Claims (5)

1. one kind is used to improve the compositions that embryo quality, control defect baby produce; it is characterized in that; it mainly by: ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid are formed, and the ratio of ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid is from 125: 125: 100: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: 10: 1.
2. be used to improve the compositions of embryo quality, the generation of control defect baby for one kind according to claim 1, the ratio that it is characterized in that ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid is from 125: 125: 100: 100: 60: 60: 10: 1 to 100: 100: 80: 80: 50: 50: 10: 1.
3. be used to improve the compositions of embryo quality, the generation of control defect baby for one kind according to claim 1, the ratio that it is characterized in that ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid is from 80: 80: 60: 60: 40: 40: 10: 1 to 100: 100: 80: 80: 50: 50: 10: 1.
4. prepare the described method for compositions that is used to improve embryo quality, the generation of control defect baby of claim 1, it is characterized in that it is made of following steps: (1) is from 125: 125: 100 in the ratio of ferrous sulfate, vitamin C, calcium gluconate, zinc gluconate, taurine, Vitamin E acetate, potassium iodate, folic acid: 100: 60: 60: 10: 1 to 80: 80: 60: 60: 40: 40: choose the acceptable material mix homogeneously at 10: 1; (2) add figuration adjuvant mix homogeneously again; (3) make oral formulations after the drying.
5. preparation according to claim 4 is used to improve the method for compositions of embryo quality, the generation of control defect baby, and it is characterized in that: described oral formulations is tablet, granule, capsule.
CN2007101085064A 2007-05-17 2007-05-17 Composition for increasing embryo quality and preventing and curing defect baby from generating Expired - Fee Related CN101306015B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2007101085064A CN101306015B (en) 2007-05-17 2007-05-17 Composition for increasing embryo quality and preventing and curing defect baby from generating
PCT/CN2008/070973 WO2008141570A1 (en) 2007-05-17 2008-05-15 A composition for improving quality of fetus, preventing and treating birth defects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007101085064A CN101306015B (en) 2007-05-17 2007-05-17 Composition for increasing embryo quality and preventing and curing defect baby from generating

Publications (2)

Publication Number Publication Date
CN101306015A CN101306015A (en) 2008-11-19
CN101306015B true CN101306015B (en) 2010-06-16

Family

ID=40031415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007101085064A Expired - Fee Related CN101306015B (en) 2007-05-17 2007-05-17 Composition for increasing embryo quality and preventing and curing defect baby from generating

Country Status (2)

Country Link
CN (1) CN101306015B (en)
WO (1) WO2008141570A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101953824B (en) * 2009-07-17 2012-12-19 中国农业大学 Application of taurine and pharmaceutically acceptable salt thereof in preparing uterine contraction inhibition drug

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198902A (en) * 1998-04-08 1998-11-18 徐云路 Nutriment for pregnant women and parturient women and its production process
CN1285163A (en) * 2000-09-10 2001-02-28 郑州生生生物工程有限公司 Nutrient soluble granules for fetus
CN1372938A (en) * 2002-02-01 2002-10-09 河北恒利集团制药股份有限公司 Composite vitamine and trace-element nutrient for gravida and puerpera
CN1823625A (en) * 2006-01-11 2006-08-30 朱阎宏 Nutritive food for pregnant and delivery woman

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10221403A1 (en) * 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Dietetic and/or pharmaceutical composition based on free aminoacids, vitamins and minerals, having specific aminoacid profile providing good immunostimulant effect

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1198902A (en) * 1998-04-08 1998-11-18 徐云路 Nutriment for pregnant women and parturient women and its production process
CN1285163A (en) * 2000-09-10 2001-02-28 郑州生生生物工程有限公司 Nutrient soluble granules for fetus
CN1372938A (en) * 2002-02-01 2002-10-09 河北恒利集团制药股份有限公司 Composite vitamine and trace-element nutrient for gravida and puerpera
CN1823625A (en) * 2006-01-11 2006-08-30 朱阎宏 Nutritive food for pregnant and delivery woman

Also Published As

Publication number Publication date
CN101306015A (en) 2008-11-19
WO2008141570A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
Warkany et al. Attempted abortion with aminopterin (4-amino-pteroylglutamic acid): Malformations of the child
STEINER et al. Absence of pituitary gland, hypothyroidism, hypoadrenalism and hypogonadism in a 17-year-old dwarf
JP2021091739A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
CN104382934A (en) Multivitamin tablet for pregnant women
DOUGLAS THE ROLE OF ENVIRONMENTAL FACTORS IN THE ETIOLOGY OF “SO-CALLED” CONGENITAL MALFORMATIONS: II. Approaches in Humans; Study of Various Extragenital Factors;“Theory of Compensatory Nutrients”, Development of Regime for First Trimester
Sutherland et al. The effect of drugs upon the developing fetus
CN105920027A (en) Application of S-ademetionine in preparation of fetus protection medicines, dysmenorrhea treatment medicines and uterus health products
Vedder Acrodermatitis enteropathica (danbolt-closs) in five siblings: Sfficacy of diodoquin in its management
CN101306015B (en) Composition for increasing embryo quality and preventing and curing defect baby from generating
CN103877115B (en) A kind of compound vitamin composition, its pharmaceutical preparation and application
Gambon et al. Megaloblastic anaemia in one of monozygous twins breast fed by their vegetarian mother
Ifeanyi et al. An update on Anaemia, Iron, Folic acid and Vitamin B 12 in Pregnancy and Postpartum
Chandraju et al. Impact of calcium and magnesium ions in identification of baby gender in High-sugar hamsters
Challa et al. Primary idiopathic hypomagnesemia in two female siblings
Laron Observations on a baby born to a mother with congenital adrenal hyperplasia
CN109288067A (en) It is a kind of to help the pregnant nutritional preparation prevented miscarriage
CN108310123A (en) A kind of pharmaceutical composition and its preparation method and application for preventing and/or treating hyperuricemia
CN101214258A (en) Medicament for improving quality of ovum and treating female infertility
Taner et al. The Effects of Multivitamin Use in Pregnancy on Mother and Fetus Health
Sumita Sharma et al. Nutritional Status of Pregnant Women in India
UA139959U (en) PHARMACEUTICAL COMPOSITION CONTAINING MIO-INOSITOL, VITAMIN B12 AND FOLIC ACID
abbas Fadhil The Effect of Vitamin D Deficiency in Women and its Symptoms and Treatment Methods
Zulkifal et al. Anemia during Pregnancy and Its Prevalence
CN110122879A (en) It is a kind of for Supplement of folic acid and the vitamin combination health food of vitamin E and preparation method thereof
AU2021261903A1 (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
DD01 Delivery of document by public notice

Addressee: Huang Shengxian

Document name: Notification to Pay the Fees

DD01 Delivery of document by public notice

Addressee: Huang Shengxian

Document name: Notification of Termination of Patent Right

DD01 Delivery of document by public notice
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20160517

CF01 Termination of patent right due to non-payment of annual fee